Physician profile
Marika A Walker
NPI 1437469970
$2,823.49
in general payments reported to CMS, 2019-2025
23 companies · $1,316 in 2025
The $1,316 reported for 2025 was more than what 85% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $439 · 2024: $1,068 · 2025: $1,316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,823.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,823.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $543.88 | 2023-2025 | Tremfya, Stelara, Simponi |
| Abbvie INC. | $463.64 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $330.73 | 2023-2025 | Entyvio, Gattex |
| Qol Medical, LLC | $195.39 | 2023-2025 | Sucraid, Sucraid |
| Gilead Sciences, INC. | $173.17 | 2024-2025 | Livdelzi |
| Genzyme Corporation | $141.91 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $122.02 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $112.93 | 2023-2025 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $100.22 | 2023-2024 | Dificid |
| Lilly USA, LLC | $76.72 | 2024-2025 | Omvoh |
| Aimmune Therapeutics, INC. | $72.36 | 2025 | Zenpep |
| Ironwood Pharmaceuticals, INC | $66.98 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $66.41 | 2024-2025 | Iqirvo |
| Madrigal Pharmaceuticals | $61.48 | 2025 | Rezdiffra |
| Ardelyx, INC. | $61.08 | 2023-2025 | Ibsrela |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Enterra Medical, INC. | $42.27 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $40.48 | 2024-2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $40.38 | 2025 | |
| Ethicon US, LLC | $30.70 | 2023 | Linx Reflux Management System |
| Celltrion USA INC. | $30.21 | 2025 | Vegzelma |
| Nestle Healthcare Nutrition INC. | $18.34 | 2023 | |
| Novo Nordisk INC | $17.39 | 2025 | Wegovy |
| Vivus LLC | $14.80 | 2023 | Qsymia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marika Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.